Safety and efficacy of tucatinib, letrozole and palbociclib in patients with previously treated HR+/HER2+ breast cancer.

Elena Shagisultanova William J Gradishar Ursa Brown-Glabberman Pavani Chalasani Andrew J Brenner Alison T Stopeck Hannah Parris Dexiang Gao Tessa Mcspadden Jose Mayordomo Jennifer R Diamond Peter Kabos Virginia F Borges

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

TLP combination was safe and tolerable. AEs were expected and manageable with supportive therapy and dose reductions. TLP showed excellent efficacy for an all-oral chemotherapy-free regimen warranting further testing.

Keyphrases

locally advanced
polycystic ovary syndrome
metastatic breast cancer
early breast cancer
stem cells
type diabetes
radiation therapy
adipose tissue
young adults
rectal cancer